Side-by-side · Research reference
LL-37vsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED15/35 cited
BFDA-ApprovedHUMAN-REVIEWED13/41 cited
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
LL-37
PT-141
Primary target
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
—
—
Origin
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
LL-37
PT-141
Endogenous expression
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
—
Exogenous (experimental)
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
—
Plasma levels (malaria)
Elevated in infected patients and miceHe 2026
Exogenous administration reduced parasitemia in murine models.He 2026
—
Evidence basis
In vitro, animal models, human observational
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Standard dose
—
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
—
PRN, max 8 doses / month
Lower / starter dose
—
1 mg (off-label)
Duration
—
PRN; reassess if no benefit after 8 doses
Reconstitution
—
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
—
≥45 min before sexual activity
04Side Effects & Safety
Parameter
LL-37
PT-141
Cytotoxicity (high dose)
Membrane disruption in host cells at supraphysiological concentrations
—
Pro-inflammatory signaling
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
—
Theoretical cancer risk
Immunomodulatory roles in tumor microenvironment under investigation
—
Flushing
—
Common, transient
Injection site reaction
—
Erythema, mild pain
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Pregnancy / OB
—
Contraindicated
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
LL-37
—PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
LL-37
PT-141
1. Natural secretion
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Experimental formulations
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
SQ — abdomen or thigh.
3. Stability considerations
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
—
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
—
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.